297 related articles for article (PubMed ID: 10942634)
21. Recent advances in the management and treatment of GI and hepatic diseases associated with HIV: Part 2.
Boyle BA
AIDS Read; 2001 Aug; 11(8):387-90, 397. PubMed ID: 11570261
[No Abstract] [Full Text] [Related]
22. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
[TBL] [Abstract][Full Text] [Related]
23. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
[TBL] [Abstract][Full Text] [Related]
24. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy.
Kim JW; Lee HS; Woo GH; Yoon JH; Jang JJ; Chi JG; Kim CY
Clin Infect Dis; 2001 Aug; 33(3):403-5. PubMed ID: 11438912
[TBL] [Abstract][Full Text] [Related]
25. [Current treatment of hepatitis B].
Suárez García E; Romero Gómez M; Grande Santamaría L
Gastroenterol Hepatol; 2001 Feb; 24 Suppl 1():35-50. PubMed ID: 11279893
[No Abstract] [Full Text] [Related]
26. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
27. Virology of hepatitis B and C viruses and antiviral targets.
Pawlotsky JM
J Hepatol; 2006; 44(1 Suppl):S10-3. PubMed ID: 16338022
[TBL] [Abstract][Full Text] [Related]
28. [Hepatitis B viral mutation and its clinical significance].
Asahina Y; Izumi N
Nihon Rinsho; 2004 Aug; 62 Suppl 8():167-74. PubMed ID: 15453309
[No Abstract] [Full Text] [Related]
29. [Chronic hepatitis B. Recent advances in diagnosis and treatment].
Bernardi M; Biselli M; Gramenzi A
Recenti Prog Med; 2002; 93(7-8):397-402. PubMed ID: 12138683
[TBL] [Abstract][Full Text] [Related]
30. Transmission of antiviral drug resistant hepatitis B virus: implications for public health and patient management.
Locarnini S
J Gastroenterol Hepatol; 2010 Apr; 25(4):649-51. PubMed ID: 20492319
[No Abstract] [Full Text] [Related]
31. Treatment predictors of a sustained virologic response in hepatitis B and C.
Kau A; Vermehren J; Sarrazin C
J Hepatol; 2008 Oct; 49(4):634-51. PubMed ID: 18715665
[TBL] [Abstract][Full Text] [Related]
32. [Chronic hepatitis B: natural history and treatments].
Bailly F; Zoulim F
Gastroenterol Clin Biol; 2002 May; 26(5):492-500. PubMed ID: 12122361
[No Abstract] [Full Text] [Related]
33. Effects of HBV gene variations on disease development and antiviral therapy for patients with chronic hepatitis B.
Chen JY; Wang LW; Sun XM; Gong ZJ
Hepatobiliary Pancreat Dis Int; 2005 Aug; 4(3):393-7. PubMed ID: 16109523
[TBL] [Abstract][Full Text] [Related]
34. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence.
Wiegand J; Hasenclever D; Tillmann HL
Antivir Ther; 2008; 13(2):211-20. PubMed ID: 18505172
[TBL] [Abstract][Full Text] [Related]
35. Treatment modalities for hepatitis B viral infection and resistance to antiviral therapy.
Pai SB; Pai RB; Schinazi RF
Panminerva Med; 2003 Sep; 45(3):165-73. PubMed ID: 14618114
[TBL] [Abstract][Full Text] [Related]
36. [Analyzing clinical character of patients resistant to lamivudine with chronic hepatitis B with YMDD mutations or non-YMDD mutations].
Yang DH; Xie YJ; Liang WF; Zhao NF
Zhonghua Gan Zang Bing Za Zhi; 2004 Aug; 12(8):496-7. PubMed ID: 15329216
[No Abstract] [Full Text] [Related]
37. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.
Lok AS; Hussain M; Cursano C; Margotti M; Gramenzi A; Grazi GL; Jovine E; Benardi M; Andreone P
Hepatology; 2000 Nov; 32(5):1145-53. PubMed ID: 11050068
[TBL] [Abstract][Full Text] [Related]
38. Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients.
Nikolaidis NL; Giouleme OI; Tziomalos KA; Saveriadis AS; Grammatikos N; Doukelis P; Voutsas AD; Vassiliadis T; Patsiaoura K; Orfanou-Koumerkeridou E; Balaska A; Eugenidis NP
J Gastroenterol Hepatol; 2005 Nov; 20(11):1721-5. PubMed ID: 16246192
[TBL] [Abstract][Full Text] [Related]
39. [Effect of single-using or combined-using lamivudine/interferon-alpha 1b on serum markers in patients with hepatitis B].
Yan J; Zhang LS; Zhao XK
Zhonghua Gan Zang Bing Za Zhi; 2003 Feb; 11(2):109-10. PubMed ID: 12648410
[No Abstract] [Full Text] [Related]
40. Lamivudine-resistant hepatitis B virus and ongoing lamivudine therapy: stop the merry-go-round, it's time to get off!
Angus P; Locarnini S
Antivir Ther; 2004 Apr; 9(2):145-8. PubMed ID: 15134176
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
